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Summary Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been
made in the long-term outcome of this disease, with the 5-year survival of patients only 30%. This poor prognosis is due to the late
presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a
superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs.
CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological
type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a
comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CYP1B1 in primary and metastatic ovarian cancer.
The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92%), with a strong
correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P = 0.005 Spearman’s rank correlation
test). In contrast no detectable CYP1B1 was found in normal ovary. © 2001 Cancer Research Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2001.1907, available online at http://www.idealibrary.com on http://www.bjcancer.comOvarian cancer is the leading cause of death from gynaecological
malignancies world-wide (Kristensen and Tropé, 1997; Anthoney
and Kaye, 1999). Each year in the UK 5000 women present with
this disease, with approximately 4000 deaths per annum in the
same time period. Definitive local surgery, typically including a
total hysterectomy, bilateral salpingo-oophorectomy and omentec-
tomy with or without lymphadenectomy (Qazi and McGuire, 1995)
is generally carried out before chemotherapy. Early tumours (stage
1a–1b) have a good prognosis and do not receive chemotherapy. 
Adjuvant chemotherapy or radiation is usually given to stage 1c
and for most patients with stage 2–4 ovarian cancer. Despite the
introduction of platinum-based chemotherapy and the taxanes,
little improvement has been made in the long-term outcome of the
disease, with the 5-year survival of patients only 30%. Poor prog-
nosis is due to the late presentation of the disease and to the unpre-
dictable response of ovarian cancer to chemotherapy (Lorrigan 
et al, 1996), as a result of intrinsic drug resistance observed in
ovarian cancer (Arts et al, 1999). 
The cytochrome P450 enzymes are a superfamily of constitutive
and inducible haemoproteins (Nelson et al, 1996) with a central
role in the oxidative metabolism of a wide range of xenobiotics
including many carcinogens (Shimada and Guengerich, 1991;
Gonzalez and Gelboin, 1994). Moreover, a number of cytochrome
P450 enzymes are able to influence the response of established
tumours to anti-cancer drugs through the activation and/or deacti-
vation of chemotherapeutic agents such as cyclophosphamide,242
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Correspondence to: MCE McFadyen paclitaxel and docetaxel, used to treat a variety of cancers
including ovarian (Le Blanc and Waxman, 1989; Sonnischen and
Relling, 1994; Kivisto et al, 1995; Marre et al, 1996; Iyer and
Ratain, 1998). 
We have previously shown that several cytochrome P450
enzymes (CYP1A, CYP1B1, CYP2C and CYP3A) are over-
expressed in a variety of tumours (Murray et al, 1993, 1994, 1997;
McKay et al, 1993; Murray 2000). In particular CYP1B1 appears
to be a tumour-related form which is over-expressed in a number
of primary tumours (Murray et al, 1997, 2001) but is undetectable
in normal tissues especially liver. We have shown strong CYP1B1
immunoreactivity in a small number of primary serous cystadeno-
carcinomas the most common histological subtype of ovarian
cancer (Murray et al, 1997). However, its presence in metastatic
tumours has not previously been investigated. 
We have recently shown that CYP1B1 inactivates docetaxel and
our in vitro studies have shown that the presence of CYP1B1 in
cells exposed to docetaxel increases the resistance of those cells to
the cytotoxic effects of this anti-cancer drug (McFadyen et al,
2001; Rochat et al, 2001). The findings that CYP1B1 may inacti-
vate docetaxel, a drug currently used as second line treatment of
ovarian cancer, and which is currently being evaluated for
licensing as first line treatment of ovarian cancer, also necessitated
a clearer understanding of the presence of CYP1B1 in the different
histological subtypes of both primary and metastatic ovarian
cancer. This study investigated the presence of CYP1B1 in both
primary and metastatic ovarian cancer. *Current address: Washington University, School of Medicine, St Louis MO 
63110-1093 USA
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Table 1 Clinicopathological characteristics of patients with ovarian cancer 
Age (median and range) 63 years (30–89 years) 
Stage of ovarian cancer 
1 44/172 (25%) 
2 15/172 (9%) 
3 103/172 (60%) 
4 10/172 (6%) 
Histological subtype 
Serous cystadenocarcinoma 102/172 (59%) 
Endometrioid carcinoma 35/172 (21%) 
Mucinous cystadenocarcinoma 24/172 (14%) 
Clear cell adenocarcinoma 7/172 (4%) 
Malignant mixed Mullerian tumour 4/172 (2%) 
Table 2 Therapeutic regimen of patients with ovarian cancer 
Treatment Number of patients 
Carboplatin 56 (32%) 
Cisplatin+cyclophosphamide 32 (19%) 
None 30 (17%) 
Carboplatin+docetaxel 15 (9%) 
Carboplatin+paclitaxel 15 (9%) 
Cisplatin+paclitaxel 9 (5%) 
Treosulphan 7 (4%) 
Cisplatin+docetaxel 4 (2%) 
No information available 2 (1%) 
XRT (radiotherapy) 1 (1%) 
Docetaxel 1 (1%) 
Total 172 (100%) MATERIALS AND METHODS 
Tissue 
Samples of ovarian cancer and corresponding normal ovary
submitted to the Department of Pathology, University of Aberdeen
for diagnosis, over a 5-year period (1993–1998), were used in this
study. Samples of primary ovarian cancer were available from 167
patients. Of these, 43 patients had corresponding synchronous
omental metastases, (i.e. both primary and metastatic tumour avail-
able for study). In addition a further 5 cases from patients with
metastatic tumours were available which had no corresponding
primary tumour (i.e. a total of 172 cases 167 + 5 = 172). In 49 out of
the 167 patients with primary ovarian cancer contralateral normal
ovarian tissue was also available for study. All the tissue samples
had been fixed in 10% neutral buffered formalin for 24 hours and
then routinely processed to paraffin wax. 
The diagnosis of ovarian cancer was performed with haema-
toxylin and eosin stained sections using standard histopathological
criteria. All tumours were reviewed by a specialist gynaecological
pathologist (IDM). The tumours were classified according to
criteria described by FIGO (Federation Internationale de
Gynecologie et d’Obstetrique). The median age of patients in this
study was 63 years with an age range from 30–89 years (Table 1).
Of the 172 patients used in this study information on treatment was
available for 170 and details are listed in Table 2. The following
anti-cancer drugs (cisplatin, carboplatin, cyclophosphamide, pacli-
taxel, and docetaxel) were used to treat the patients. Most patients
received either cisplatin or carboplatin. The other 3 drugs were
usually given in combination in a platinum-based regime. © 2001 Cancer Research CampaignFollowing diagnosis, the disease status of patients was assessed
by 2 gynaecological oncologists as follows, at 3 monthly intervals
for the first year, at 6 monthly intervals for the following 2 years,
and thereafter. If patients had stable disease or were disease-free,
they were seen at yearly intervals. Following surgical debulking
only 19% of patients remained disease-free over the period of
follow-up, 42% had recurrent disease with a median disease-free
interval of 23 months and an overall disease-free range of 1 to + 70
months, 39% of the patients had incomplete tumour debulking at
surgery and showed no disease-free interval. The median overall
survival of the patients was 17 months with an overall survival
range of 1 to at least +70 months. 
Immunohistochemistry 
In this study a monoclonal antibody (MAb) raised against a 15
amino acid peptide located in the C-terminal third of the human
CYP1B1 protein (McFadyen et al, 1999) was used to identify sites
of CYP1B1 immunoreactivity. Immunohistochemical detection of
CYP1B1 was performed using a peroxidase-based tyramine signal
amplification method as described previously (McFadyen et al,
1999). 
Sections of normal ovary and ovarian cancer were dewaxed,
rehydrated and washed in cold water, prior to heat-based antigen
retrieval in 0.01 M citrate buffer, pH 6 for 20 minutes. The
sections were then immunostained with the anti-CYP1B1 mono-
clonal antibody. Sites of CYP1B1 immunoreactivity were identi-
fied using a fluorescein tyramide technique (NEN, Hounslow,
Middlesex, UK) with diaminobenzidine as the enzyme substrate.
Sections of breast cancer which had previously been shown to
contain CYP1B1 by immunohistochemistry (McFadyen et al,
1999) were used as the positive control. The negative control used
TBS in place of the primary antibody. 
To establish the presence or absence of CYP1B1 and its distrib-
ution, intensity and cellular localization, the sections were counter-
stained with haemotoxylin and examined using bright field light
microscopy by 2 independent observers (MCEM, GIM). CYP1B1
immunoreactivity in the tumours was assessed as either strong (3),
moderate (2), weak (1) or negative (0). Tumours exhibiting
CYP1B1 immunoreactivity in more than 5% of the cells were
considered as positive. A tumour was classified as negative if less
than 5% of tumour cells showed positive immunoreactivity
(McFadyen et al, 1999). 
Statistics 
Statistical analysis including survival analysis was performed
using SPSS version 7.5 for Windows 95™. The comparison
between CYP1B1 expression in primary and metastatic ovarian
cancer was performed using the Spearman’s rank correlation test.
Comparison between survival, CYP1B1 status and the different
chemotherapeutic treatments was performed with the Kaplan–
Meier log rank test. 
RESULTS 
Immunohistochemistry 
Primary ovarian cancer 
CYP1B1 immunoreactivity was identified in the majority (92%) of
ovarian cancers and was specifically localized to the cytoplasm ofBritish Journal of Cancer (2001) 85(2), 242–246
244 MCE McFadyen et al tumour cells (Figure 1). In addition, there was no apparent intratu-
mour heterogeneity. In a high percentage of the ovarian cancers
there was moderate (23%) or strong (51%) immunoreactivity for
CYP1B1, while in a minority of cases (17%) there was weak
immunostaining for CYP1B1 only 8% of ovarian cancers showed
no CYP1B1 immunostaining (Table 3). The different stages of
ovarian cancer all exhibited a high level of CYP1B1 expression:
stage 1, 91%; stage 2, 73%; stage 3, 95% and stage 4, 90%. A high
level of expression was also observed for the different histological
subtypes, serous 92%; mucinous 87%; endometrioid 94%; mixed
malignant Mullerian 100% and clear cell 86%. 
Metastatic ovarian cancer 
The presence of CYP1B1 was observed in the majority (94%) of
metastases with a high proportion showing moderate (46%) or
strong (38%) immunoreactivity, weak (10%) immunoreactivity or
absence (6%) of immunoreactivity was found in a minority of
cases (Table 4). There was no detectable CYP1B1 expression in
any of the normal ovarian tissue samples (Figure 1). 
Similar levels of CYP1B1 expression were exhibited for the
different histological subtypes in both primary and metastatic
tumour (serous, mucinous endometrioid and clear cell) (Tables 3
and 4). The comparison between CYP1B1 expression in primary
ovarian cancer and metastatic deposits showed a significant corre-
lation (P = 0.005 Spearman’s rank correlation test) (Table 5). 
In this investigation there was no significant difference in
survival of patients on different chemotherapeutic treatments. In
addition, the presence of CYP1B1 generally had no effect on the
survival of patients on the different treatments. However, in the
small group of patients treated with docetaxel either singly or in
combination with a platinum-based agent (n = 20), a trend towards
a poorer overall survival was observed, in those patients with
moderate or strong CYP1B1 immunoreactivity (Kaplan–Meier log
rank test P = 0.2716) (Figure 2). British Journal of Cancer (2001) 85(2), 242–246
Table 3 The number of cases showing CYP1B1 ex
primary ovarian cancer 
Diagnosis
Negative
Serous cystadenocarcinoma 8
Endometrioid carcinoma 2
Mucinous cystadenocarcinoma 3
Clear cell adenocarcinoma 1
Malignant mixed Mullerian tumour 0
Total 14
Table 4 The number of cases of CYP1B1 expres
metastatic ovarian cancer 
Diagnosis
Negative
Serous cystadenocarcinoma 2
Endometrioid carcinoma 0
Mucinous cystadenocarcinoma 0
Malignant mixed Mullerian tumour 1
Total 3
*48 cases comprised of 43 cases with omental me
plus 5 cases with metastatic disease but no corresDISCUSSION
This study has investigated the presence of CYP1B1 in a large
number of both primary and metastatic ovarian tumours, utilizing a
monoclonal antibody to CYP1B1 to demonstrate the localization of
CYP1B1 to ovarian tumour cells and lack of expression in normal
ovarian tissue. The over-expression of CYP1B1 was observed in all
the histological subtypes of epithelial ovarian cancer and at high
frequency. This is in agreement with a pilot study which utilized a
polyclonal antibody to CYP1B1 (Murray et al, 1997), and showed
the over-expression of CYP1B1 in a small number (n = 7) of serous
cystadenocarcinomas investigated. This is the most common histo-
logical subtype found in patients suffering from this malignancy.
We have previously shown the over-expression of CYP1B1 protein
in a wide variety of primary malignant tumours of different histoge-
netic types and the lack of detectable CYP1B1 protein in normal
tissue (Murray et al, 1997). However, no information is available
on the presence of CYP1B1 in metastatic disease. It is important to
determine the phenotype of the metastatic disease as it may not
reflect that of the primary tumour. 
Due to the lack of available tissue from metastatic deposits,
tissue from the primary tumour is often used to predict the
response of the metastatic tumour to chemotherapy (McLeod et al,
2000). This may not be a true reflection of the biological pheno-
type of the metastatic tumour, indeed differential expression of
several proteins has previously been observed between primary
and metastatic tumours (McKay et al, 2000). These differences in
expression are likely to affect the response of metastatic lesions to
chemotherapy. Spread of ovarian cancer is through the peritoneal
cavity and one of the key findings of this current study is the high
frequency of CYP1B1 over-expression observed in the majority 
of metastatic tumours. Indeed this study is the first to describe 
the over-expression of CYP1B1 in metastatic tumours. A highly
significant correlation of CYP1B1 immunoreactivity was observed© 2001 Cancer Research Campaign
pression in the different histological types of
CYP1B1 immunoreactivity 
Weak Moderate Strong Total 
15 22 54 99 
7 13 13 35 
4 4 12 23 
3 0 3 7 
0 0 3 3 
29 39 85 167 
sion in the different histological types of
CYP1B1 immunoreactivity 
Weak Moderate Strong Total 
4 20 13 39 
1 0 4 5 
0 2 0 2 
0 0 1 2 
5 22 18 48* 
tastases and corresponding primary tumour
ponding primary tumour. 
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between the primary and metastatic tumours (P = 0.005 Spearman’s
rank correlation test). 
Table 5 Comparison of CYP1B1 immunoreactivity in paired samples of
primary and metastatic ovarian cancer 
CYP1B1 in primary tumour 
Negative Weak Moderate Strong Total 
Negative 1 0 0 2 3 
Weak 0 1 2 1 4 
Moderate 1 3 5 10 19 
Strong 0 0 3 14 17 
Total 2 4 10 27 43 
P = 0.005 Spearman’s rank correlation test. 
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Figure 2 Survival of patients treated with docetaxel as part of their anti-
cancer drug regimen and classified according to CYP1B1 status of their
primary tumours. The presence of strong/moderate CYP1B1
immunoreactivity results in a poorer overall survival compared with weak or
absent CYP1B1 immunoreactivity (Kaplan–Meier log rank test P = 0.2716) 
A B
C D
E F
Figure 1 The immunohistochemical localization of CYP1B1 in different
histological subtypes of ovarian cancer and in metastatic deposits. CYP1B1
immunoreactivity is localized to tumour cells. CYP1B1 immunoreactivity is
present in both primary tumour and in metastatic deposits and is absent in
normal ovary. (A) Serous cystadenocarcinoma; (B) mucinous
cystadenocarcinoma; (C) endometrioid carcinoma; (D) clear cell
adenocarcinoma; (E) normal ovary; (F) metastatic serous
cystadenocarcinoma In this study a trend suggesting a poorer survival was shown in
those patients with moderate or strong CYP1B1 immunoreactivity
who received docetaxel either as a single agent or in combination
with a platinum-based agent, compared to those patients with low
or negative CYP1B1 immunoreactivity. Although, this finding
was not statistically significant (Kaplan–Meier log rank test P =
0.2716), this may be due to the small number of patients treated
with docetaxel. However, this finding supports our in vitro studies
and the concept that CYP1B1 inactivates docetaxel and increases
the resistance of cells expressing CYP1B1 to the cytotoxic effects
of this anti-cancer drug (McFadyen et al, 2001; Rochat 2001).
Therefore, further investigation with a larger population is
required to ascertain whether CYP1B1 does contribute signifi-
cantly to the response of ovarian cancer to docetaxel. 
We have recently shown that CYP1B1 interacts with a number
of structurally diverse clinically useful anti-cancer agents in a
substrate-dependent manner (Rochat et al, 2001). Therefore, in
addition to being a mechanism of docetaxel drug resistance it is
likely that CYP1B1 is a mechanism of drug resistance to a variety
of anti-cancer drugs. The findings that CYP1B1 immunoreactivity
was over-expressed in the majority of primary and metastatic
tumours, and the lack of detectable CYP1B1 in normal tissue
including the ovary, also highlights CYP1B1 as a target for the
development of novel chemotherapeutic agents which could be
activated by this P450 (Murray et al, 1997; McFadyen et al, 1999). British Journal of Cancer (2001) 85(2), 242–246
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